{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-001606","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.534533+00:00","generated_at":"2026-06-04T09:01:46.165651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenetic Biosciences reports FY2023 net loss of $4.1M; cash at $9.0M","bullets":["Net loss of $4.1M for year ended Dec 31, 2023; R&D expenses down 26.7% to $3.5M.","Royalty payments from Takeda sublicense rose 48.8% to $2.5M in 2023.","Cash and cash equivalents of $9.0M at year-end to fund operations.","Advancing DNase-based oncology platform targeting pancreatic carcinoma toward Phase 1 trial.","Entered research funding and material transfer agreement with University of Virginia."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-001606","json":"https://secwatch.observer/filing/0001683168-24-001606.json","markdown":"https://secwatch.observer/filing/0001683168-24-001606.md","text":"https://secwatch.observer/filing/0001683168-24-001606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824001606/0001683168-24-001606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824001606/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:01:46.165651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53370a76d31642182603c97e0655b9c02c96bb8e","claim":"Xenetic Biosciences, Inc. reported the year ended December 31, 2023 results: net income approximately $4.1 million.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was approximately $4.1 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824001606/0001683168-24-001606-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"approximately $4.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}